Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease on Donepezil

NCT00829374 is registered in ClinicalTrials.gov with Medivation, Inc. as lead sponsor.

NCT NCT00829374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00829374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease on Donepezil
Lead sponsor
Medivation, Inc.
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2009
Completion date
December 31, 2011
Enrollment
1,003 (actual)
Sites
101

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease